FDA Accepts Application for Oral Epinephrine Film
The potential new rescue medication for severe allergies faces a regulatory decision date of March 16, 2027.
Updated on Oct. 15, 2026 in Allergies
Live Poll
Do you believe oral delivery methods will make it easier to manage severe allergic reactions?
The FDA has accepted the resubmitted New Drug Application for Anaphylm, an oral epinephrine film designed to treat severe allergic reactions. This development sets a target action date of March 16, 2027, for the potential first-of-its-kind rescue medication.
Why it matters
If approved, this product would offer an alternative to traditional injectable epinephrine for people managing Type I allergic reactions. The agency move marks a key step in resolving questions previously raised about the drug candidate.
The resubmission is supported by positive findings from human factors and pharmacokinetic studies, which follow the FDA's January 30, 2026, Complete Response Letter. The final regulatory approval remains pending until the review process concludes.
The players
Aquestive Therapeutics
A pharmaceutical company specializing in orally administered drug delivery platforms.
FDA
The federal agency responsible for evaluating the safety and efficacy of new drug applications.
The details
Anaphylm is designed as a sublingual film that uses a polymer matrix-based delivery technology to administer an epinephrine prodrug. This delivery method aims to provide a rapid way to manage severe Type I allergic reactions without the need for needles. Aquestive Therapeutics submitted the new data to address specific regulatory items identified earlier this year.
Timeline
January 30, 2026: FDA issued a Complete Response Letter.
August 2026: Positive human factors and pharmacokinetic study results were announced.
September 16, 2026: The company submitted the formal NDA resubmission.
October 15, 2026: The FDA accepted the application for review.
March 16, 2027: The FDA's target PDUFA goal action date.
Health Landscape
The potential approval of this film would introduce the first oral rescue option for severe allergies to the current standard of care. This milestone follows the structured review timeline mandated by the Prescription Drug User Fee Act (PDUFA) process.
This development represents a potential future shift in how severe allergic reactions are managed, though the drug is not yet available for use. Patients should discuss existing epinephrine treatment plans with their doctor and ensure they remain prepared for emergency care.
The takeaway
Anaphylm represents a shift toward non-injectable options for treating severe allergic reactions. Patients should continue to rely on current prescribed epinephrine devices and talk to a healthcare provider about any future changes in emergency management protocols.
What happens next
The FDA is expected to reach a final decision on the application by March 16, 2027.
Further reading
For more on evolving treatment options, visit our Allergies section.
Live Poll
Do you believe oral delivery methods will make it easier to manage severe allergic reactions?
